1. Home
  2. HKIT vs GRDX Comparison

HKIT vs GRDX Comparison

Compare HKIT & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKIT

Hitek Global Inc.

HOLD

Current Price

$2.84

Market Cap

28.3M

Sector

Technology

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$3.25

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKIT
GRDX
Founded
1996
N/A
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3M
28.6M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
HKIT
GRDX
Price
$2.84
$3.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
37.5K
127.5K
Earning Date
04-24-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.95
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$1.87
52 Week High
$8.80
$6.93

Technical Indicators

Market Signals
Indicator
HKIT
GRDX
Relative Strength Index (RSI) 46.70 42.96
Support Level $2.36 $3.30
Resistance Level $3.34 $3.65
Average True Range (ATR) 0.20 0.40
MACD -0.05 -0.03
Stochastic Oscillator 10.19 4.26

Price Performance

Historical Comparison
HKIT
GRDX

About HKIT Hitek Global Inc.

Hitek Global Inc is a provider of information technology consulting and solutions services. The company has two lines of business services to small and medium businesses, which consist of Anti-Counterfeiting Tax Control System tax devices, including Golden Tax Disk and printers, ACTCS services, and IT services; and services to large businesses, which include hardware sales and software sales. It generates revenues from Hardware and equipment sales, Tax services, and Software sales.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: